Sagent Turns Generic Injectable Shortages Into Business Opportunity
This article was originally published in PharmAsia News
Executive Summary
The specialty generic manufacturer has a facility dedicated to producing shortage drugs, a seemingly endless commercial opportunity given the development, regulatory and reimbursement challenges in the sterile injectable space.
You may also be interested in...
Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence
Nichi-Iko Pharmaceutical Co. Ltd. will pay $736m in cash for Sagent Pharmaceuticals Inc. in a deal that will further expand the Japanese company's biosimilars business beyond Asia and diversify the US generics firm's injectable medicines portfolio.
Nichi-Iko Buys Sagent To Strengthen US Biosimilars Presence
Nichi-Iko Pharmaceutical Co. Ltd. will pay $736m in cash for Sagent Pharmaceuticals Inc. in a deal that will further expand the Japanese company's biosimilars business beyond Asia and diversify the US generics firm's injectable medicines portfolio.
GDUFA’s Perfect Storm: Approvals Drop, Submissions Jump
FDA increases “complete response” and refuse-to-receive actions in the first half of FY 2014 compared to the previous year, efforts the agency says will move pending applications closer to approval.